论文部分内容阅读
目的观察周剂量拓扑替康治疗晚期卵巢癌的疗效和安全性。方法晚期卵巢癌癌患者25例,治疗方案为:拓扑替康3mg/m2,第1、8、15天给药,4周为1个周期,共6个周期,根据患者的毒性反应调整剂量及疗程,至少治疗2周期评价疗效。结果CR2例,PR15例,NC4例,PD4例。拓扑替康的总有效率为68%(17/25)。主要毒副反应为血液学毒性,血液学毒性主要为白细胞减少,多为Ⅰ~Ⅱ度,共7例,占28%;Ⅲ度1例,占4%;Ⅳ度0例,占0%。血红蛋白下降2例(8%),血小板下降3例(12%),均为Ⅰ~Ⅱ度。非血液学毒性较轻微。无化疗相关性死亡。结论周剂量拓扑替康治疗晚期卵巢癌疗效好,毒副反应轻。
Objective To observe the efficacy and safety of weekly topotecan in the treatment of advanced ovarian cancer. Methods Twenty-five patients with advanced ovarian cancer were enrolled in this study. The treatment regimen was topotecan 3mg / m2, on the 1st, the 8th and the 15th day, one cycle for 4 weeks, a total of 6 cycles. According to the patients’ toxicity, Course of treatment, at least 2 cycles to evaluate the efficacy. Results CR2 cases, PR15 cases, NC4 cases, PD4 cases. Topotecan total effective rate was 68% (17/25). The main toxicities were hematological toxicity. The main hematological toxicities were leukopenia, mostly grade Ⅰ ~ Ⅱ, with a total of 7 cases, accounting for 28%. Grade Ⅲ was 1 case, accounting for 4%. Grade Ⅳ was 0 case, accounting for 0%. Hemoglobin decreased in 2 cases (8%), thrombocytopenia in 3 cases (12%), were Ⅰ ~ Ⅱ degrees. Non-hematologic toxicity is minor. No chemotherapy-related death. Conclusion Weekly topotecan treatment of advanced ovarian cancer efficacy, toxicity and light.